Goyama Susumu, Yamamoto Go, Shimabe Munetake, Sato Tomohiko, Ichikawa Motoshi, Ogawa Seishi, Chiba Shigeru, Kurokawa Mineo
Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Cell Stem Cell. 2008 Aug 7;3(2):207-20. doi: 10.1016/j.stem.2008.06.002.
Evi-1 has been recognized as one of the dominant oncogenes associated with murine and human myeloid leukemia. Here, we show that hematopoietic stem cells (HSCs) in Evi-1-deficient embryos are severely reduced in number with defective proliferative and repopulating capacity. Selective ablation of Evi-1 in Tie2(+) cells mimics Evi-1 deficiency, suggesting that Evi-1 function is required in Tie2(+) hematopoietic stem/progenitors. Conditional deletion of Evi-1 in the adult hematopoietic system revealed that Evi-1-deficient bone marrow HSCs cannot maintain hematopoiesis and lose their repopulating ability. In contrast, Evi-1 is dispensable for blood cell lineage commitment. Evi-1(+/-) mice exhibit the intermediate phenotype for HSC activity, suggesting a gene dosage requirement for Evi-1. We further demonstrate that disruption of Evi-1 in transformed leukemic cells leads to significant loss of their proliferative activity both in vitro and in vivo. Thus, Evi-1 is a common and critical regulator essential for proliferation of embryonic/adult HSCs and transformed leukemic cells.
Evi-1已被公认为是与小鼠和人类髓系白血病相关的主要致癌基因之一。在此,我们表明Evi-1缺陷胚胎中的造血干细胞(HSC)数量严重减少,增殖和再填充能力存在缺陷。在Tie2(+)细胞中选择性敲除Evi-1可模拟Evi-1缺陷,这表明Tie2(+)造血干/祖细胞需要Evi-1发挥功能。在成年造血系统中条件性删除Evi-1显示,Evi-1缺陷的骨髓造血干细胞无法维持造血功能并丧失其再填充能力。相比之下,Evi-1对于血细胞谱系定向分化并非必需。Evi-1(+/-)小鼠表现出造血干细胞活性的中间表型,表明Evi-1存在基因剂量需求。我们进一步证明,在转化的白血病细胞中破坏Evi-1会导致其在体外和体内的增殖活性显著丧失。因此,Evi-1是胚胎/成年造血干细胞和转化的白血病细胞增殖所必需的共同关键调节因子。